Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 6/20 | 0.47 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.45 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.45 |
| ▸ | NAALAD2 | Q9Y3Q0 | 2/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 1/20 | 0.44 |
| ▸ | MME | P08473 | 3/20 | 0.44 |
| ▸ | ECE1 | P42892 | 2/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | CASP9 | P55211 | 1/20 | 0.42 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.42 |
| ▸ | APC | P25054 | 1/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1663151 | 0.94 | CTSL (0.44) | FOLH1NAALAD2CTSLCTSBCTSS | |
| SCHEMBL1663148 | 0.87 | APC (0.51) | FOLH1NAALAD2CTSLCTSBCTSS | |
| SCHEMBL1661066 | 0.83 | AVPR1A (0.44) | NAALAD2 | |
| SCHEMBL1662059 | 0.83 | CTSL (0.54) | CTSLCTSBCTSSCTSKMME | |
| SCHEMBL1660926 | 0.80 | CTSL (0.56) | CTSLCTSBCTSSCTSKCASP1 | |
| SCHEMBL1662080 | 0.79 | BACE1 (0.49) | NAALAD2 | |
| SCHEMBL30688507 | 0.78 | ITGB3 (0.58) | FOLH1ITGB3ITGA2BCTSLCTSB | |
| SCHEMBL30688544 | 0.78 | ITGB3 (0.58) | FOLH1ITGB3ITGA2BCTSLCTSB | |
| SCHEMBL30688553 | 0.78 | ITGB3 (0.58) | FOLH1ITGB3ITGA2BCTSLCTSB | |
| SCHEMBL2494968 | 0.78 | ITGB3 (0.59) | FOLH1ITGB3ITGA2BCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170240592-A1 | GADD45BETA/MKK7 INHIBITOR FOR THE TREATMENT OF A RESISTANT HAEMATOLOGICAL MALIGNANCY | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2017-08-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170240592-A1 | GADD45BETA/MKK7 INHIBITOR FOR THE TREATMENT OF A RESISTANT HAEMATOLOGICAL MALIGNANCY | MCL1, DDIT3, MAP2K7 | FOLH1 3761/4885ITGB3 4189/4885ITGA2B 3470/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.